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Abstract
Background: Active and passive immunotherapy in both amyloid-beta precursor protein (APP) transgenic mice
and Alzheimer’s Disease (AD) patients have resulted in remarkable reductions in amyloid plaque accumulation,
although the degree of amyloid regression has been highly variable. Nine individuals with a clinical diagnosis of
AD dementia were actively immunized with the Ab peptide 1-42 (AN-1792) and subjected to detailed postmortem
biochemical analyses. These patients were compared to 6 non-immunized AD cases and 5 non-demented control
(NDC) cases.
Results: All patients were assessed for the presence of AD pathology including amyloid plaques, neurofibrillary
tangles and vascular amyloidosis. This effort revealed that two immunotherapy recipients had dementia as a
consequence of diseases other than AD. Direct neuropathological examination consistently demonstrated small to
extensive areas in which amyloid plaques apparently were disrupted. Characterization of Ab species remnants by
ELISA suggested that total Ab levels may have been reduced, although because the amounts of Ab peptides
among treated individuals were extremely variable, those data must be regarded as tentative. Chromatographic
analysis and Western blots revealed abundant dimeric Ab peptides. SELDI-TOF mass spectrometry demonstrated a
substantive number of Ab-related peptides, some of them with elongated C-terminal sequences. Pro-inflammatory
TNF-a levels were significantly increased in the gray matter of immunized AD cases compared to the NDC and
non-immunized AD groups.
Conclusions: Immunotherapy responses were characterized by extreme variability. Considering the broad range of
biological variation that characterizes aging and complicates the recognition of reliable AD biomarkers, such
disparities will make the interpretation of outcomes derived from epidemiologic and therapeutic investigations
challenging. Although in some cases the apparent removal of amyloid plaques by AN-1792 was impressive,
proportionate alterations in the clinical progression of AD were not evident. The fact that plaque elimination did
not alter the trajectory of decline into dementia suggests the likelihood that these deposits alone are not the
underlying cause of dementia.
Background
Alzheimer’s disease (AD) dementia affects over 26 mil-
lion elderly individuals worldwide with this number pro-
jected to quadruple by 2050 [1]. In the USA alone, 5.3
million people are afflicted with AD at an estimated
annual cost of $172 billion [2]. Given these alarming
epidemiological data, devising strategies and therapeutic
interventions to prevent, mitigate or delay the age of
onset of this dementia is urgent.
The deposition of amyloid-beta (Ab) peptides in the
brains of patients with AD has been a principal focus of
intense research since the seminal publications of Glen-
ner and Wong [3] and Masters et al. [4]. The observa-
tion of profuse accumulation of parenchymal and
vascular Ab peptides in AD brains was integrated into
the amyloid cascade hypothesis as the central causative
factor in the pathogenesis of AD dementia [5,6]. Genetic
and biochemical studies of amyloid-beta precursor pro-
tein (APP), presenilin (PS) 1 and PS2 mutations, all of
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which enhance amyloid deposition, strongly support this
hypothesis. For many AD researchers, the amyloid
hypothesis has attained a status of virtual dogma. How-
ever, there are dissidents who have critically questioned
this powerful tenet [7,8].
The APP and Ab peptides are evolutionarily conserved
molecules with multiple functions. It has been suggested
that Ab may serve a neurogenic function in the develop-
ment of neural stem cells [9]. It has also been postulated
that Ab binds neurotoxic substances and that amyloido-
sis stimulates their phagocytic removal, thus represent-
ing a physiological response to injury [10,11]. A decline
in b- and g-secretase activities decreases Ab production,
inducing neuronal death [12]. The Ab peptides are
powerful modulators of microglial activation [13,14],
have vasoconstrictor activity [15] that may have a pro-
tective role in neuroinflammation and inhibit angiogen-
esis [16]. A hemostatic function for the Ab deposited in
the walls of the cerebral microvasculature has also been
postulated [17,18].
Transgenic (Tg) mouse models have been engineered
to express well-characterized APP, PS and tau muta-
tions. These mice are widely utilized to test the efficacy
of various compounds and strategies intended to allevi-
ate the deleterious effects of Ab peptide accumulation
or promote its specific clearance. Special attention has
been devoted to amyloid peptide immunization thera-
pies to determine their effects on pathology and cogni-
tion. Both active and passive immunotherapy in Tg
mice successfully reduced amyloid plaque accumulation
and cognition deficits (reviewed in reference [19]).
Unfortunately, these promising interventions have yet to
produce unequivocal therapeutic benefit in human clini-
cal trials. Several factors may explain discrepancies
between Tg animal and human AD patient responses to
amyloid immunotherapy. Transcriptome analyses have
revealed that the murine response to aging is very differ-
ent from that of humans [20]. In addition, differences in
lifespan, intrinsic rates of aging, the relative simplicity of
mouse brains and the nature of the induced lesions
artificially imposed upon the mice models, may also
account for these differences [21-23].
Multiple clinical and pathological observations, in
demented individuals, including the biochemical compo-
sition of amyloid plaques, suggest that the pathogenesis
of AD is a complex and multifactorial process involving
more than Ab. In support of these tenets are the neuro-
pathological, biochemical and immunochemical studies
performed on the brains of Ab-immunized individuals.
Although there were obvious extensive areas in which
amyloid plaques were absent, the amount of vascular
amyloid and soluble Ab apparently increased while neu-
rofibrillary tangles (NFT) were unaffected [24-31]. More
importantly, despite anti-Ab immunization during a
period of mild to moderate cognitive impairment, all
patients exhibited continued, progressive dementia and
eventually died with AD [29]. Furthermore, Ab immu-
notherapy clinical trials have been fraught with frustra-
tions. The AN-1792 clinical trial was halted after 6% of
the immunized population developed aseptic menin-
goencephalitis [32]. More recently, the Bapineuzumab
passive immunotherapy clinical trial was complicated by
the development of brain vasogenic edema in some indi-
viduals carrying the apolipoprotein (ApoE) ε4 allele,
which compelled the elimination of these subjects from
the trial [33]. Notwithstanding these adverse events,
recent analyses of AD AN-1792 immunized individuals
revealed an apparent reduction in neurite and tau
pathology [34,35].
In this paper, we report the neuropathological and
biochemical changes observed in a cohort of 9 indivi-
duals clinically diagnosed with AD that were actively
immunized with fibrillar Ab1-42 under the label of AN-
1792. We compare the present results with our previous
investigations of 2 AN-1792 immunized cases [28], and
with data derived from 6 untreated AD cases and 5
non-demented control (NDC) individuals.
Methods
Human Subjects
The study involved 9 individuals clinically diagnosed
with AD who were actively immunized with the Ab pep-
tide 1-42 (AN-1792). Six of these cases were provided
by Dr. J. Nicoll, University of Southampton School of
Medicine (USSM) and 3 by Dr. E. Masliah, University of
California San Diego (UCSD) (Table 1). For comparison,
6 non-immunized AD cases and 5 NDC cases were pro-
vided by Dr. T. Beach, Banner Sun Health Research
Institute (BSHRI). In the immunized group (n = 9), the
mean patient age of death was 81 years, 2 were female
and 7 were male with a mean disease duration of 8
years. In the NDC individuals, cases # 1-5, the mean age
of death was 82 years (2 females and 3 males), and in
the AD group, cases # 6-11, the mean age of death was
82 years (5 females and 1 male) with a mean disease
duration of 9 years. Their individual ages, gender, ApoE
genotype, disease duration, and when applicable, immu-
nogen doses, number of injections and antibody titers as
well as the survival time after the application of the first
immunization doses are given in Table 1. Of the 9
immunized individuals with a clinical diagnosis of AD,
upon postmortem examination, two cases were classified
as non-AD dementia cases (# 21 from USSM and # 22
from UCSD), having the neuropathological diagnoses of
progressive supranuclear palsy (PSP) and hippocampal
sclerosis (HS) with severe frontal lobe atrophy, respec-
tively. One case (# 19) was neuropathologically diag-
nosed as a Lewy body variant of AD.
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Morphological assessments
The BSHRI AD and NDC cases were assessed for total
plaque score, plaque density, total NFT score, Consor-
tium to Establish a Registry for Alzheimer’s disease
(CERAD), neuritic plaque score, Braak stage, total WMR
and total CAA score (see Table 2). Detailed evaluations
of these neuropathological parameters are given in a
previous publication [36]. Semi-quantitative appraisal of
plaque clearance, subjectively attributed to immunother-
apy, was estimated as none (0), mild (+), moderate (++)
and extensive (+++). The evaluation of CAA content in
the UCSD cases was performed by lysing 10 cubes of
cerebral cortex tissue (~ 1 cm per side) in 100 ml 10%
SDS, 10 mM Tris-HCl pH 7.4. After 48 h of continuous
stirring at room temperature the only remaining
structures were the tufts of insoluble blood vessels and
attached amyloid deposits. After removal of the deter-
gent, the vessels were air dried on glass slides and
stained with thioflavine-S [17].
Clinical, neuropathological and long-term effects of
Ab42 immunization for the AD patients # 12-15, origi-
nating from USSM, have been thoroughly described else-
where [29,30,35]. The neuropathology reports for cases #
19, 20 and 22 from UCSD are summarized in Table 3.
Quantification of soluble and insoluble Ab by ELISA
All steps were performed at 4°C. Gray matter tissue (100
mg) was homogenized with a Teflon tissue grinder in 6
volumes of 20 mM Tris-HCl, 5 mM EDTA, pH 7.8 with
protease inhibitor cocktail (PIC, Roche Diagnostics,
Table 1 Clinical characteristics and immunization details of study subjects
Case ID Expired age
(years)
Gender ApoE
genotype
Disease
Duration (years)
Imm.
Dose (μg)
# of
injections
Mean antibody response
(ELISA units)
PIST
(months)
NDC
1-BSHRI 77 F 2/3 - - - - -
2-BSHRI 81 F 4/4 - - - - -
3-BSHRI 83 M 3/4 - - - - -
4-BSHRI 88 M 2/3 - - - - -
5-BSHRI 81 M 3/3 - - - - -
Mean 82
AD
6-BSHRI 76 F 4/4 6 - - - -
7-BSHRI 82 M 3/4 7 - - - -
8-BSHRI 86 F 3/4 5 - - - -
9-BSHRI 80 F 3/3 12 - - - -
10-BSHRI 85 F 3/3 9 - - - -
11-BSHRI 81 F 4/4 15 - - - -
Mean 82 9
Immunized AD*
12-USSM 71 F 3/4 10 225 8 1:4072 44
13-USSM 81 M n/a 7 50 8 1:1707 57
14-USSM 82 M 3/4 6 50 8 1:4374 60
15-USSM 81 M 4/4 11 225 7 1:491 63
16-USSM 88 F 3/3 11 50 7 1:137 86
19-UCSD 78 M 3/4 5 50 1 n/a 36
20-UCSD 86 M 3/4 9 50 1 n/a 60
Mean 81 8 6 58
Immunized non-ADD*
21-USSM
PSP
79 M 2/3 6 50 8 < 1:100 51
22-UCSD
HS
80 M 3/3 5 50 1 n/a 48
NDC, non-demented control; AD, Alzheimer’s disease; non-ADD, non-Alzheimer’s disease dementias; ApoE, apolipoprotein E; Imm., immunization; PIST, post-
immunization survival time; F, female; M, male; BSHRI, Banner Sun Health Research Institute; USSM, University of Southampton School of Medicine; USCD,
University of California San Diego; n/a, not available; PSP, progressive supranuclear palsy; HS, hippocampal sclerosis.
* Immunization data for USSM cases taken from Holmes, et al [29], Boche, et al [30] and Boche, et al [35].
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Mannheim, Germany). The homogenates were centri-
fuged at 435,000 × g for 20 min in an Optima TLA-
ultracentrifuge using a 120.2 rotor (Beckman, Fullerton,
CA). The supernatant was saved as the soluble Ab frac-
tion and total protein quantified with the Pierce BCA
protein assay (Rockford, IL). Four-hundred mg each of
gray and white matter tissue was homogenized in 3 ml
of 90% glass distilled formic acid (GDFA) and centri-
fuged at 250,000 × g for 20 min at 4°C in an Beckman
LE-80K ultracentrifuge using a SW41 rotor (Beckman).
The supernatant was collected carefully avoiding the top
fat layer. Specimens were homogenized in 90% GDFA
with the aim of fully solubilizing all forms of Ab (fibril-
lar, diffuse, membrane-bound, and intra- and extra-
cellular oligomeric species). High-speed centrifugation
permitted the removal of all lipids including membrane-
associated forms which are totally disrupted by the
GDFA and form a compact aggregate at the top of the
centrifuge tube. The entire volume from each case was
submitted to fast protein liquid chromatography (FPLC)
size-exclusion Superose-12 chromatography in 80%
GDFA mobile phase (see below). The Ab peptide-
containing fractions were collected and pooled from
each run and reduced to 2 ml by vacuum centrifugation
(SpeedVac; Savant/Thermo, Waltham, MA). To remove
the acid, each case was dialyzed in 1000 MW cutoff tub-
ing against 2 changes of water (1 h each) and 2 changes
of 0.1 M ammonium bicarbonate solution (1 h each).
Table 2 Neuropathology of study subjects
Case ID Ab42
load (%)
Plaque clearance Brain
weight (g)
Total WMR
score
Total plaque
score
Plaque
density
Total NFT
score
Cerad
NP
Braak
stage
Total CAA
score
NDC
1 - - 950 n/a 6.0 zero 2.0 not AD I n/a
2 - - 1275 0 7.6 sparse 3.0 not AD II 2
3 - - 1385 0 1.0 zero 1.0 not AD I 0
4 - - 1260 4 6.8 moderate 4.3 possible
AD
III 3
5 - - 1190 0 12.5 sparse 6.4 not AD III 5
AD
6 - - 1100 0 13.5 moderate 8.8 probable
AD
IV 4
7 - - 1145 0 13 frequent 13 definite
AD
V 5
8 - - 1055 n/a 13.25 frequent 8.75 definite
AD
V 4
9 - - 765 9 12.5 frequent 14.5 definite
AD
VI 1
10 - - 960 0 12.25 frequent 12 definite
AD
V 0
11 - - 970 10 13.25 frequent 15 definite
AD
VI 10
Immunized AD*
12 4.68 + n/a n/a n/a n/a n/a n/a VI n/a
13 3.32 ++ 1120 n/a n/a n/a n/a n/a VI n/a
14 0.05 +++ 1200 n/a n/a n/a n/a n/a VI n/a
15 2.71 ++ n/a n/a n/a n/a n/a n/a VI n/a
16 2.99 + n/a n/a n/a n/a n/a n/a VI n/a
19 n/a n/a 1208 n/a n/a n/a n/a n/a III n/a
20 n/a n/a 1162 n/a n/a n/a n/a n/a IV n/a
Immunized non-ADD*
21 PSP 0.75 0 n/a n/a n/a n/a n/a n/a n/a n/a
22 HS n/a n/a 1280 n/a n/a n/a n/a n/a n/a n/a
NDC, non-demented controls; AD, Alzheimer’s disease; non-ADD, non-Alzheimer’s disease dementias; PSP, progressive supranuclear palsy; HS, hippocampal
sclerosis; WMR, white matter rarefaction; NFT, neurofibrillary tangle; NP, neuritic plaque; CAA, cerebral amyloid angiopathy; n/a, not available. Plaque clearance
designations correspond to 0, none; +, little evidence or active process; ++, moderate/patchy; +++, complete.
*Ab42 load and Braak stage for USSM cases taken from Holmes, et al [29], Boche, et al [30] and Boche, et al [35].
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Samples were freeze-dried and lyophilized. The samples
were then reconstituted in 500 μl of 5 M guanidine
hydrochloride (GHCl) prepared in 50 mM Tris-HCl, pH
8.0 and shaken overnight at 4°C. Total protein was
quantified by the Pierce BCA protein assay. The ELISA
kits to quantify Ab40 and Ab42 were obtained from
Invitrogen (Carlsbad, CA) and Innogenetics (Gent,
Belgium), respectively, and performed following the
manufacturer’s instructions.
Quantification of tumor necrosis factor-a (TNF-a) by
ELISA
All steps were performed at 4°C and followed a pre-
viously published protocol [37]. Gray matter (100 mg)
was homogenized in 20 volumes of 20 mM HEPES, 1.5
mM EDTA, pH 7.4 in PIC (Roche) with an Omni TH
electric tissue grinder and the samples centrifuged at
3000 × g for 15 min in an IEC Centra CL3R centrifuge
(Thermo, Waltham, MA). The supernatant was then
collected and centrifuged at 40,000 × g for 1 h with a
50.4 Ti rotor (Beckman) and Optima LE-80K ultracen-
trifuge (Beckman). The supernatant was again collected
and total protein determined with a BCA protein assay
(Pierce). Human TNF-a levels were measured with a kit
from PromoKine (Heidelberg, Germany) according to
the manufacturer’s instructions.
Western Blot Analysis
Western blots were performed as previously described
[38]. Briefly, gray matter was homogenized in RIPA
buffer (Sigma, St. Louis, MO), containing PIC (Roche).
The homogenates were centrifuged, the supernatants
collected and total protein quantified with a BCA pro-
tein assay kit (Pierce). The samples (25 μg of total pro-
tein loaded per lane) were separated by SDS-PAGE
and then electrophoretically transferred onto 0.45 μm
pore nitrocellulose membranes (Invitrogen), blocked
with 5% non-fat milk in phosphate-buffered saline
(PBS), 0.5% Tween 20 (Fluka, St. Louis, MO). The pri-
mary antibodies used in the experiments included
22C11 (recognizes amino acids 66-81 of APP; Milli-
pore, Billerica, MA), CT9APP (recognizes the last 9
C-terminal amino acids of APP; Millipore) and anti-
tau HT7 (recognizes amino acids 159-163; Pierce). The
secondary antibodies used were either goat anti-mouse
IgG conjugated horseradish peroxidase (HRP; 22C11
and anti-tau) or goat anti-rabbit IgG conjugated HRP
(CT9APP) from Pierce. Protein signals were detected
with SuperSignal WestPico Chemiluminescent (Pierce)
substrate, CL-Xpose film (Pierce) and Kodak GBX
developer and fixer (Sigma). Analysis was performed
with a GS-800 calibrated densitometer (Bio-Rad,
Hercules, CA) and Quantity One software (Bio-Rad).
All membranes were stripped with Restore™ Western
Blot Stripping Buffer (Pierce), washed in PBS and then
re-blocked. Anti-mouse or anti-rabbit actin antibodies
(Abcam, Cambridge, MA) were used to re-probe the
blots for total protein normalization.
Fast protein liquid chromatography
Cerebral cortex (~ 3 g) was minced and homogenized in
18 ml of 90% GDFA, allowed to stand at room tempera-
ture for 15 min and centrifuged at 240,000 × g for 1 h
at 4°C. The separated lipid layer collected at the top of
the tube was carefully removed and the small pellet at
the bottom of the tube discarded. The intermediate
supernatant was divided into 500 μl portions and frozen
at -80°C. Each aliquot was submitted to size-exclusion
FPLC using a Superose 12 column (10 × 300 mm, Gen-
eral Electric, Uppsala, Sweden), equilibrated with 80%
GDFA. The chromatography was developed using 80%
GDFA at a flow rate of 15 ml per h at room tempera-
ture and monitored at 280 nm. The fraction that eluted
between 50-66 minutes, containing 2-8 kDa Mr mole-
cules, was collected and reduced to ~50 μl by vacuum
centrifugation (Savant Instruments Inc), and stored
at -80°C.
High performance liquid chromatography (HPLC)
The 2-8 kDa FPLC fractions were separated by reverse-
phase HPLC using a C8 column (4.6 × 250 mm, Zorbax
SB, Mac Mod) using a linear gradient from 0-60% water-
acetonitrile concentration containing 0.1% trifluoroacetic
acid (TFA), developed at a flow rate of 1 ml per min over
120 min at 80°C. Absorbance was monitored at 214 nm
and a total of 9 fractions collected and reduced in volume
by vacuum centrifugation. To eliminate the acid, the spe-
cimens were washed with three changes of water (200 μl
Table 3 Summary of Clinico-Neuropathology Analysis in UCSD AN-1792-Immunized Cases
Case ID Blessed [63] MMSE Total plaque Neuritic plaques Tangles CAA Neuropathology diagnosis
19 26 8 23 7 0 3 Lewy body Variant of AD
20 17 18 50 0 0 2 AD
22 28 10 4 3 0 0 HS, severe frontal lobe atrophy
MMSE, mini-mental state examination; CAA, cerebral amyloid angiopathy; AD, Alzheimer’s diease; HS, hippocampal sclerosis. The counts are representative from
the frontal cortex. For each case, 3 sections were analyzed. Total plaques include diffuse and mature with a maximum score of 50 (100 × magnification). Neuritic
plaques are defined as those containing a corona of dystrophic neurites with a maximum score of 50 (100 × magnification). Tangles were assessed at 400 ×
magnification with a maximum score of 50. CAA was assessed as 0, none; 1, mild; 2, moderate; 3, severe using thioflavine-S staining.
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each) and the volume reduced by vacuum centrifugation.
After the last wash, the volume was reduced and the
samples re-solubilized in 2xLDS sample loading buffer
(Invitrogen) with 50 mM dithiothreitol. Western blots
were conducted as described above with anti-Ab40 and
anti-Ab42 (Invitrogen) and CT9APP (Millipore) as
primary antibodies and goat a-rabbit IgG HRP as the
secondary antibody.
Surface enhanced laser desorption/ionization-time of
flight mass spectrometry (SELDI-TOF) mass spectrometry
(MS). Ab40/42 Method
HPLC peaks that were analyzed using Western blots and
found to contain Ab were subjected to SELDI-TOF MS
following a previously published protocol [39]. Briefly,
the capture antibodies, anti-Ab40 and anti-Ab42 antibo-
dies (Invitrogen), were loaded onto PS20 ProteinChip
arrays (Bio-Rad, Hercules, CA) at a concentration of
0.38 mg/ml. Either the HPLC Ab-containing peaks or
Ab1-40 or 1-42 peptide standards (positive controls)
were then applied. The molecular mass assignments
resulted from 100 averaged shots in a Bio-Rad SELDI
Protein Biology System II with external calibration
attained using the ProteinChip Peptide Mass Calibration
Kit (Bio-Rad).
SELDI-TOF MS, 6E10 Method, ProteinChip
b-Amyloid MPD Kit
The HPLC peaks containing Ab were pooled together to
yield one combined sample per case. All steps were per-
formed at room temperature. The internal standard and
calibrants were prepared according to the manufac-
turer’s instructions (Bio-Rad). To each HPLC and cali-
brant sample (Ab peptides: 1-16, 1-38, 1-40 and 1-42),
50 μl/ml of the internal standard AbCys1-24 (Mr =
2,979.3) was added. Each spot on the ProteinChip arrays
was equilibrated with 5 μl of PBS for 5 min, then loaded
with 5 μl of sample or calibrant and incubated in a
humidified chamber for 1 h. The samples/calibrants
were removed and each array was washed 3 times in a
15 ml conical tube with 10 ml of wash buffer (PBS, 0.5%
Triton X-100) for 5 min each then 3 times in PBS for 5
min each. To desalt the arrays, each chip was washed in
10 ml of 0.1 M HEPES for 5 min and then air dried. To
5 mg of a-cyano-4-hydroxycinnamic acid (CHCA), 200
μl of acetonitrile and 200 μl of 1.0% TFA were added.
The solution was vortexed for 2 min then centrifuged at
1000 × g for 1 min to remove particulates. A 20% solu-
tion of CHCA was made from the saturated CHCA
(diluted in a 1:1 ratio of acetonitrile and 1.0% TFA) and
vortexed for 1 min. The 20% CHCA solution was
applied (1 μl) to each spot and air dried. The molecular
mass assignments and calibration was performed as
described above.
Results
I. Clinical and Neuropathological Observations
We examined 9 individuals clinically diagnosed with AD
who were treated with the AN-1792 immunotherapy.
Whole mount preparations of cortical blood vessels of
cases # 19, 20 and 22, after removal of brain parench-
yma by SDS, revealed the presence of insoluble CAA
(Figure 1). For comparative reference, Table 2 shows the
neuropathological parameters observed in 5 NDC indivi-
duals (cases # 1-5) and 6 non-immunized AD patients
(cases # 6-11). The neuropathological changes observed
in 5 immunized cases originating from USSM (cases #
12 -16), who were treated with the AN-1792 antigen,
were described in previous publications [29,30,35]. Their
Ab42 load and semi-quantitatively estimated degree of
plaque clearance and Braak stage are given in Table 2.
This group of individuals each received 7-8 antigen
injections, at 50 or 225 μg per dose, and had an average
survival time of 62 months (range 44-86 months) after
the initial immunization (Table 1). Four of these indivi-
duals were ApoE genotyped, and of these, three were
carriers of the ApoE ε4 allele.
The USSM case # 21, clinically diagnosed as having
AD, received 6 immunizations of 50 μg each (Table 1).
However, on neuropathological examination, this case
was reclassified as PSP. Accordingly, the Ab42 load was
very low (0.75%) (Table 2), and the levels of soluble and
insoluble Ab as measured by ELISA were also negligible
(Table 4).
Table 3 gives an account of clinical and neuropatholo-
gical data for the three cases provided by UCSD. Cases
# 19 and # 20 were recognized after postmortem neuro-
pathological examination as Lewy body variant of AD
and AD, respectively. The immunized patient # 22, clini-
cally diagnosed as AD, was found to be a case of HS on
neuropathological examination and also had low levels
of Ab compared to the average of the immunized AD
group (Table 4). All three individuals received only a
single dose of the AN-1792 antigen.
II. Ab ELISA Quantification
Pivotal in the assessment of immunotherapy effectiveness
is the quantification of Ab40, Ab42 and total Ab peptides
by ELISA, as Tris-soluble and GDFA/GHCl-soluble
forms in gray matter (GM) and white matter (WM).
Frozen WM was not available from USSM for ELISA
analysis. These values are shown in Table 4. For compari-
son, analogous values observed in non-immunized AD
and NDC individuals are also presented in Table 4.
Significant differences in Ab levels between the NDC and
AD populations in both GM and WM tissue compart-
ments were observed for GM GDFA/GHCl Ab42 and
total Ab GM GDFA/GHCl levels (p = 0.0026 and 0.0066,
respectively, unpaired, 2-tailed t-test).
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The overall degree of variability in the total Ab levels in
the GM of the immunized AD cases is enormous, ranging
from 283 to 14,011 ng/mg total protein (mean = 6,544) for
GDFA/GHCl-soluble species and from 0 to 13,431 pg/mg
of total protein (mean = 3,467) for the corresponding
Tris-soluble Ab fractions (Table 4). There are remarkable
differences concerning the final outcome of immunother-
apy as illustrated by subjects # 13 and 14. Both individuals
received 8 AN-1792 injections of 50 μg (Table 1). In the
latter case, the histological observations [29,30] were
matched by ELISA quantification which revealed com-
paratively lesser amounts of total soluble and insoluble Ab
peptides, while case # 13 had the second highest levels of
GDFA/GHCl-soluble Ab and the highest levels of Tris-
soluble Ab observed. In contrast, case # 14 had the lowest
levels of Ab in both solvents compared to the immunized
group. In these two individuals, the survival time since the
first immunization was almost identical: 57 and 60
months, illustrating that the presence or absence of Ab
amyloid plaque pathology was apparently irrelevant for the
progression and fatal outcome with AD dementia.
A comparison of the average Ab levels between immu-
nized and non-immunized AD groups also demonstrates
large overall differences in soluble and insoluble Ab
content (Table 4). There is a statistically significant dif-
ference in the GDFA/GHCl-soluble Ab42 between
immunized and non-immunized individuals (p = 0.039),
being lower in the former group. On the other hand, the
levels of Ab40 were increased paradoxically in the immu-
nized cohort, almost to twice the mean quantities
observed in the non-immunized AD control group,
although the difference did not reach statistical signifi-
cance. In one immunized individual (case # 14) the level
of total Tris-soluble Ab fell below the limit of detection.
The mean of the remaining 6 immunized individuals was
22 times greater than the mean observed in the non-
immunized AD cases.
Given the high degree of pathological variability
encountered among NDC, AD and Ab-immunized AD
patients, as shown in Table 4, it is also important to
consider weighing the data individually, rather than
exclusively working with group mean values. For exam-
ple, in the NDC group, both GM and WM GDFA/
GHCl-soluble Ab levels of case # 5 were abnormally
high for this group and consequently skews the average
values for this group upward to a range of 4-5-fold
greater than the mean of the other members of the
NDC group. Hence, this case should be classified as a
non-demented ‘high pathology control’. In the AD
group, the GDFA/GHCl-soluble Ab in WM of indivi-
dual # 11 is abnormally high for this group and again
skews the average values upward, being 7 times greater
than the mean value observed in the rest of the group.
In the immunized group, the WM GDFA/GHCl-soluble
total Ab level in case # 20 is 13 times greater than the
values observed for case # 19. In the Tris-soluble Ab
fraction, the immunized AD individuals # 13 and # 16
have 21- and 12-fold more Ab, respectively, than the
remaining 5 individuals in this group. These elevated
values are also reflected, although to a lesser degree, in
the GM GDFA/GHCl-soluble Ab fractions and are cor-
related with only moderate and mild plaque clearance
[29,30]. Dixon’s Q test [40] also identified these indivi-
duals as outliers.
Interestingly, 3 of the 7 immunized neuropathologi-
cally confirmed AD cases had a total GM GDFA/GHCl-
soluble Ab values substantially lower than the mean of
the 6 non-immunized AD cases (7218 ng/mg total pro-
tein), suggesting that the antibodies may have removed
Ab in these cases. The remaining 4 immunized cases
had values equal to or higher than the mean observed
in the non-immunized AD group.
As mentioned above, of the 3 cases treated with the
AN-1792 immunogen that were provided by UCSD, one
Figure 1 Thioflavin-S of blood vessels to assess CAA in UCSD cases using SDS lysates of cerebral cortex. A) Case # 19 demonstrated
severe CAA. B) Case # 20 showed moderate CAA. C) Case # 22 exhibits moderate CAA, although this case was neuropathologically reported as
having no CAA (Table 3). These differences may be due to different methodological assessments or sampling sites. Scale bar = 250 μm.
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was neuropathologically diagnosed as HS. The remain-
ing 2 individuals, cases # 19 and # 20, exhibited the
neuropathology of AD, as shown in Table 3. From the
Ab immunoassay standpoint, case # 19 had relatively
moderate levels of GM and WM GDFA/GHCl-soluble
Ab peptides as well as Tris-soluble Ab. In contrast, case
# 20 showed the highest levels of GM and WM GDFA/
GHCl-soluble Ab peptides of the 20 cases under investi-
gation including the 5 NDC and 6 non-immunized AD
cases that served as controls.
In addition, there was also a high degree of variability in
antibody response (Table 1). For example, case # 12 and
case # 14 had the highest antibody titers, but from a
neuropathological point of view, case # 12 had little evi-
dence of plaque removal, while case # 14 had extensive Ab
clearance. The Ab ELISA data also show a similar pattern
for case # 12 and case #14 (Table 4). Case # 15 had a rela-
tively low antibody titer, but demonstrated a moderate
amount of Ab clearance (Table 2). Case # 21 had a low
antibody titer which in the immunization context was irre-
levant, since this was in an individual with PSP.
III. Apolipoprotein E genotype
Six out of seven patients neuropathologically diagnosed
as AD were ApoE genotyped. Five of them were carriers
for the ε4 allele (Table 1). There was no direct
Table 4 ELISA quantification of TNF-a, Ab40 and Ab42
GM GM GDFA/GHCl-soluble Ab WM GDFA/GHCl-soluble Ab GM Tris-soluble Abb
TNF-a pg/
mg total
protein*
Ab40 ng/
mg total
protein
Ab42 ng/
mg total
protein**#
Total Ab ng/
mg total
protein***
Ab40 pg/
mg total
protein
Ab42 pg/
mg total
protein
Total Ab
pg/mg total
protein
Ab40 pg/
mg total
protein
Ab42 pg/
mg total
protein
Total Ab
pg/mg total
protein
NDC
1 24 15 488 503 102 454 556 0 0 0
2 13 82 911 993 82 428 510 166 438 604
3 14 4 105 109 83 429 512 0 0 0
4 12 56 920 976 66 570 636 0 0 0
5 17 167 2168 2335 81 2596 2677 0 142 142
Mean 16 65 918 983 87 836 923 28 97 124
AD
6 11 5405 8152 13557 101 4122 4223 116 138 254
7 13 374 5910 6284 923 2379 3302 0 88 88
8 13 179 4773 4952 90 5156 5246 148 93 241
9 13 394 2664 3058 136 965 1101 254 66 320
10 15 96 5344 5440 91 1931 2022 0 35 35
11 18 7169 2847 10016 8940 13669 22609 151 0 151
Mean 14 2269 4948 7218 1714 4704 6417 112 70 182
Immunized AD
12 45 6347 58 6405 - - - 1260 0 1260
13 37 9925 1226 11151 - - - 13169 262 13431
14 32 252 31 283 - - - 0 0 0
15 32 1067 421 1488 - - - 629 26 655
16 43 8568 1570 10138 - - - 7556 142 7698
19 33 764 1565 2329 661 2141 2802 498 0 498
20 34 6315 7696 14011 7363 29669 37032 565 160 725
Mean 34 4748 1795 6544 4012 15905 19917 3382 84 3467
Immunized non-ADD
21
PSP
30 1 18 19 - - - 0 0 0
22 HS 13 3 333 336 158 1245 1403 0 0 0
* p < 0.0001; **p = 0.026; ***p = 0.007 unpaired, 2-tailed t-tests between AD and NDC cases. # p = 0.039 unpaired, 2-tailed t-tests between non-immunized and
immunized AD individuals. NDC, non-demented control; AD, Alzheimer’s disease; non-ADD, non-Alzheimer’s disease dementias; TNF, tumor necrosis factor; GM,
gray matter; WM, white matter; GHCl, guanidine hydrochloride, GDFA, glass-distilled formic acid; PSP, progressive supranuclear palsy; HS, hippocampal sclerosis.
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correlation between the ApoE status and the total
amount of GM Ab extracted by GDFA/GHCl or those
present in the Tris-soluble fractions (Table 4).
IV. Tumor necrosis factor-a ELISA quantification
Tumor necrosis factor-a is a proinflammatory cytokine
which was elevated by an average of 2.4 times in AD-
immunized individuals when compared to the mean
levels observed in non-immunized AD (34 pg/mg total
protein, 14 pg/mg total protein, respectively; p < 0.0001,
Table 4). It is noteworthy that even in the immunized
AD patient with the most marked reduction in Ab (#
14), the TNF-a level remained higher than in the non-
immunized AD group (Table 4).
V. Western blots of gray matter homogenates
Cerebral cortex from the 9 immunized cases was directly
homogenized in RIPA buffer and analyzed by Western
blots using the 22C11, CT9APP and tau HT7 antibodies.
For comparison, 4-5 AD and 4 NDC cases were also
incorporated. The N-terminal-directed antibody 22C11
demonstrated no significant differences in total APP
among the immunized cases as compared to non-immu-
nized AD and NDC individuals (Figure 2A). However,
there were some fluctuations in the amount of 25 kDa
APP N-terminal peptide (Figure 2A). The CT9APP anti-
body detected the CT99/83 at ~13 kDa and a band at
~40 kDa which was present in all specimens under investi-
gation (Figure 2B). This peptide, revealed by the CT9APP
antibody, is of interest because a band of similar size is
also present in PS mutations in sporadic AD and in NDC
cases [38] as well as in the triple transgenic mice (3XTg)
engineered by LaFerla et al. (A. Roher, unpublished obser-
vations). Further investigation is needed to clarify the nat-
ure of this putatively longer APP C-terminal peptide and
its proteolytic products. There was no difference in the
levels of CT99 (~13 kDa band) between the AD immu-
nized cases and non-immunized AD cases. It is possible
that the 25 and the 40 kDa bands represent complemen-
tary N-terminal and C-terminal species derived from the
unmodified APP molecule. The CT9APP antibody also
revealed that the amount of total APP was moderately
decreased in the immunized cases when compared to
non-immunized AD and NDC groups, although 22C11
did not show this trend. This antibody also demonstrated
two additional APP C-terminal related bands at ~ 58 and
~ 75 kDa (Figure 2B). These observations go with the
caveat that 22C11 and CT9APP can cross react with amy-
loid precursor-like protein (APLP). An overall comparison
of the Western blot HT7 tau antibody pattern demon-
strated no significant differences among AD immunized
and non-immunized samples, with the exception of the
AD cases # 7 and # 9 that exhibited a SDS-resistant
dimeric form of tau (Figure 2C).
VI. Column Chromatography
After initial separation by FPLC, the fractions contain-
ing the Ab peptides which were eluted between 50-62
min (equivalent to 12.5-15.5 ml of elution solvent),
were separated through C8 reverse-phase HPLC
(Figure 3). Biochemical characterization by Western
blot was performed on 3 of the immunized cases. Case
# 19 had a decreased amount of predominantly
dimeric Ab42 peptides relative to Ab40 isoforms
(Figure 3A). The AN-1792 case # 20, on the other
hand, had equimolar levels of Ab40 and Ab42 peptides
(Figure 3B). The HS case # 22 had very small amounts
of Ab40 and a more abundant complement of Ab42-
related peptides. Western blots probed with CT9APP
antibody demonstrated the presence of the expected
CT99 and CT83 APP C-terminal fragments at about
13 kDa in Figure 3C. In addition, they also showed a
peptide band with a Mr of ~40 kDa.
VII. Mass spectrometry
In a previous study dealing with the remnant Ab-related
peptides left in the brains of 2 AD individuals immunized
with the AN-1792, we identified a large number of pep-
tides by matrix-assisted laser desorption/ionization-time
of flight mass spectrometry (MALDI-TOF MS). The pre-
sence of these peptides was confirmed by reflectron
MALDI-TOF in their monoisotopic Mr form [28]. In the
present investigation, 3 (cases # 20-22, from UCSD) out
of the 9 cases under study were investigated by mass
spectrometry. SELDI-TOF MS was used to identify the
Ab-related peptides using Ab40, Ab42 and 6E10 as cap-
ture antibodies. An assortment of Ab-related peptides
were identified with N-termini starting at 1, 2, 3-pyroglu-
tamyl (3pE), 4, 5, 6, 11, and 17 and C-termini ending at
40, 42, 43, 46, 47, 49, 50, 61, 62, 68, 73, 82, 96 and 99
(data given in the Ab-related amino acid sequencing,
where residue 99 corresponds to residue 695 of the
APP695 molecule, see Table 5). Dimers of Ab 2-40 and
1-43 as well as dimeric Ab hybrids identified as 3pE-40 +
4-40 and 3pE-40+ 2-40 were observed. As can be appre-
ciated, there are several longer Ab-related peptides cover-
ing amino acid sequences beyond the transmembrane
domain of the APP. Our studies revealed secretase
cleavage at the b-sites 1 and 11, at the a-site 17, and at
putative g-sites 40, 42, 43, 46, 47, 49, and 50. Shorter N-
terminal Ab sequences were found starting at residues 2,
3, 4, 5, and 6, probably resulting from aminopeptidase
activity, as it is commonly observed in all AD cases [41].
Post-translational modifications such as cyclization of
residue 3 glutamyl to pyroglutamyl [42] oxidation of Met
and random formylation of Ser and Thr were also
observed. The latter modification was probably an artifact
of exposure of the specimens to formic acid. Although
quantification of peptides by MS is difficult to achieve
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Figure 2 Western blots of GM homogenates. A total of 25 μg of protein was loaded in each lane. A) 22C11 against amino acid residues 66-
81 of APP, B) CT9APP against the last nine amino acid residues of APP and C) tau HT7 against amino acid residues 159-163 of tau. For further
details see the Results Section. IMZ, immunized; AD, Alzheimer’s disease; NDC, non-demented control.
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due to the convoluted mixture of peptides that hinders
the rate of laser ionization, in AD there is a strong pre-
ponderance of dimeric Ab-related oligomers relative to
the number of monomers as suggested by our HPLC/
Western blot studies (see Figure 3) and other studies per-
formed in our laboratory that suggest dimeric Ab as the
most stable and abundant oligomeric association [43-45].
Discussion
The outcome of active and passive Ab immunization in
APP transgenic mice models and AD patients is consis-
tent with efficient amyloid plaque disruption, although
the degree of senile core regression has been highly vari-
able among both the treated rodents and humans. At
present, more than 40 Ab immunotherapy clinical trials
involving about 10,000 subjects are being actively pur-
sued (Alzheimer Research Forum; http://www.alzforum.
org/new/detail.asp?id=2409; April 2, 2010). Interestingly,
in phase II clinical trials, passive immunotherapy with
Bapineuzumab showed no statistical significance in the
two primary outcome measures (ADAS-cog and Disabil-
ity Assessment for Dementia), although post hoc explora-
tory analyses on a smaller population of completers
showed some small therapeutic effects [33,46]. However,
it remains to be established whether or not anti-amyloid
immunotherapy will lead to a clear improvement in cog-
nition and quality of life enhancement for AD patients or
even arrest dementia progression.
The urgent need for trustworthy biomarkers for AD is
well illustrated by the proportion of potentially con-
founding clinical misdiagnoses discovered in the present
study. Two out of the 9 individuals clinically diagnosed
with AD dementia were subsequently recognized
Figure 3 Gray matter of UCSD immunized cases separated by HPLC (C8 reverse-phase). The figure shows the HPLC chromatogram
fractions that were investigated by Western blotting developed with anti-Ab40 and anti-Ab42 and CT9APP antibodies. The diagonal-hyphenated
line represents the acetonitrile gradient. Lanes 10 contain the standards Ab40 or Ab42 synthetic peptides. A) and B), correspond to the
neuropathologically confirmed AD cases # 19 and # 20, respectively. C) corresponds to the neuropathologically confirmed hippocampal sclerosis.
m, Ab monomer; d, Ab dimer; t, Ab trimer.
Table 5 SELDI-TOF peptides captured with Ab40 and
Ab42 antibodies and 6E10
Mr Observed Mr Calculated Peptide Sequence
3371.2 3373.0 17-49 (2f)
3442.2 3444.1 17-50 (f)
3486.1 3488.1 17-50 (ox/2f)
4514.5 4514.1 1-42
4925.5 4924.7 2-47
4940.7 4942.6 1-46 (ox)
5371.4 5670.8 11-62
6178.3 6177.2 6-61 (3f)
6723.3 6724.9 11-73 (ox)
7178.2 7180.3 4-68 (3ox)
8202.0 8204.1 3pE-40 + 4-40 (4ox)
8411.7 8412.3 3pE-40 + 2-40 (ox/2f)
8450.4 8445.4 dimer 2-40 (ox)
8565.4 8563.9 5-82
9265.5 9262.4 dimer 1-43 (2ox)
9273.0 9273.7 17-99 (4ox)
9624.0 9623.1 11-96 (ox)
f, formyl; ox, oxygen; pE, pyroglutamyl.
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neuropathologically as PSP and HS cases. Interestingly,
observations from our own brain bank at BSHRI indicate
that only about 50% of the AD cases should be consid-
ered neuropathologically uncomplicated AD [36]. The
remainder represents AD pathology combined with other
neurodegenerative disorders, which produce severe cog-
nitive and intellectual deterioration, such as vascular
dementia, dementia with Lewy bodies, fronto-temporal
dementia, Parkinson’s disease, PSP, HS, or dementia
without distinctive pathology. In the absence of a reliable
clinical diagnosis for AD and confronted by the near or
total absence of amyloid plaques in many autopsied
patients who received immunotherapy, it is impossible to
be certain that all these individuals actually exhibited AD
plaque pathology at the onset of treatment or were at
risk of developing this pathology. The introduction of
imaging techniques for the detection of amyloid plaque
burden such as those based on contrast-producing Ab
binding dye compounds exemplified by Pittsburgh com-
pound-1 (11C-PiB-PET) will be of assistance in selecting
candidates suitable for immunotherapy.
Detailed postmortem examinations of AN-1792 clini-
cal trial participants have been undertaken by our
research group and others [24-31]. A critical observation
is the wide range of responses to immunotherapy
reflected in the extreme variability in Ab peptide levels
among treated individuals as revealed by immunoassay
studies. Assuming that the treatment commenced in
patients possessing a full complement of amyloid pla-
ques, neuropathological examination consistently
demonstrated localized to extensive areas in which
senile plaques apparently were disrupted. In addition,
ELISA analyses suggest that in some cases the total
amount of Ab was reduced as a consequence of therapy.
This inter-patient variability indicates that it will be
necessary to personalize treatment regimens and titrate
doses precisely to enoptimal efficacy and safety.
Our previous report [28] examined 2 AD cases immu-
nized with the AN-1792 antigen. In one of these cases,
the patient received 2 intramuscular doses of 225 μg of
the immunogen. Nine months after the second immuni-
zation the patient developed non-terminal aseptic menin-
goencephalitis. In the second case, 3 doses of 225 μg
were administered and the patient died one year after the
first immunization as a result of “failure to thrive”. Both
individuals carried ApoE ε3/ε4 genotypes. In both cases,
postmortem examination revealed that some areas of the
brain exhibited near complete apparent amyloid plaque
disruption with solubilization, but without Ab clearance
from the brain. Both vascular and diffuse amyloid depos-
its resisted AN-1792 disruption. The total amount of
GHCl-soluble Ab in the patient who developed menin-
goencephalitis was 868 μg/g wet weight compared to 186
μg/g wet weight in the second patient. The mean Ab
values in non-immunized AD (n = 31) and NDC (n =
22) were 406 μg/g wet weight and 221 μg/g wet weight,
respectively [28]. However, while overall trends can be
equated, these values are not directly comparable to
those in the present study because the Ab extraction
technique was different and the scale of the reported
means were different as well, being presented in ng/mg
of total protein versus μg/g wet weight. As in the present
study, total Ab peptide levels varied widely between the
two cases. Tris-soluble Ab was 4.5 times higher and
GHCl WM Ab was 5.7 times higher in the meningoence-
phalitis case when compared to the second case. In the
two immunized cases from the previous paper, the levels
of Tris-soluble Ab were increased over the levels in the
NDC and non-immunized AD groups [28]. The same
trend was repeated in the current study, where the AD
immunized cases (with the exception of case # 14) had
higher levels of Tris-soluble Ab than in the means of the
AD and NDC populations. In our previous study, there
also was an apparent substantial increase in the amount
of vascular amyloid deposits as assessed by thioflavine-S
staining [28].
The fact that elimination of amyloid plaques did not
alter the trajectory of decline into dementia [29] was a
disappointment and suggests the disquieting possibility
that amyloid plaques alone are not the direct underlying
cause of dementia. Several recent studies have demon-
strated that after a follow-up of two years, 11C-PiB
uptake remains unchanged in patients with AD [47,48].
However, while amyloid deposits were stable, there was
a significant decrease (~ 20%, p = 0.01) in regional
metabolic rate for glucose [48]. Furthermore, serial
11C-PiB-PET and MRI in NDC, mild cognitive impair-
ment (MCI) and AD patients demonstrated that amyloi-
dosis alone is not sufficient to produce cognitive decline
which appears to be driven by brain atrophy and neuro-
degeneration [49]. Interestingly, the volumes of ventricu-
lar expansion continue to increase as time progresses in
NDC (1.3 ml/year), MCI (2.5 ml/year) and AD (7.7 ml/
year), a manifestation of either natural aging or brain
pathology-associated atrophy [49]. Amyloid plaques,
although undoubtedly noxious, may represent a rescue
program for the brain to manage Ab accumulation [50].
Some studies have suggested that soluble dimeric
Ab-species represent the most toxic forms of these
molecules [44,51] signifying that an exclusive focus on
amyloid plaque remediation is simply too limited.
Notwithstanding disappointment in the fact that dis-
ruption of amyloid plaques neither cured dementia nor
halted its progression, it is too soon to pronounce this
strategy a failure. First and foremost, the hypothesis that
amyloid plaques are the prime dementia-causing pathol-
ogy has not yet been tested rigorously. Biochemical dis-
section has revealed that amyloid plaques are more than
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accumulated Ab, but actually represent complex multi-
molecular assemblages [52,53]. Postmortem examina-
tions have revealed that some amyloid plaques are not
reversed completely by immunotherapy [28] and rem-
nants, dubbed “collapsed” plaques [25] or “moth-eaten”
plaques [27] composed of insoluble molecules persist. It
is possible that despite the impressive morphological
effects of immunotherapy, “amyloid plaque skeletal rem-
nants” harbor toxic moieties and continue to exert a
deleterious legacy effect on dementia development. In
addition, the Ab spectrum composing plaque deposits
may be sufficiently diverse in structure to thwart com-
plete disruption by the immunotherapeutic agents
employed to date. The humanized monoclonal antibo-
dies that recognize the Ab molecule N-terminus [46]
will fail to recognize the terminally-truncated Ab species
demonstrated to be prevalent in human senile plaques
[41]. Furthermore, diffuse plaques lack surrounding
reactive microglia and fall short of eliciting an inflam-
matory response [54,55]. This phenomenon may be due
to the absence of the Ab HHQK domain that binds to
the glycosaminoglycans on the surface of microglia
[13,14]. Furthermore, diffuse plaques that are mainly
composed of P3 (Ab residues 17-42 [56]), may elude
disruption by immunotherapy directed to the N-term-
inal domain of Ab. The a-secretase cleavage does not
generate amyloidogenic peptides and therefore it has
been considered a favorable therapeutic pathway. How-
ever, there is evidence supporting the contention the P3
activates JNK and caspase-8 resulting in neuronal apop-
tosis [57]. In addition to amyloid and diffuse plaque
deposits, AD patients harbor NFT and these lesions
have persisted in patients who have received anti-Ab
immunotherapy [24,25,27,28,31,35]. Because several dis-
tinct classes of pathological and biochemical lesions
typically co-exist in AD patients, a complete cure for
dementia may simply need to address more than amy-
loid plaques.
The broad-scale, chronic use of anti-amyloid plaque
immunotherapy is complicated by the fact that the fun-
damental function(s) of the evolutionarily-conserved Ab
molecules remain unknown. One possibility is that amy-
loid deposits perform a vascular damage rescue function
by forming a patch wherever the blood brain barrier
(BBB) is breached [17]. Studies in transgenic mice and
humans reveal that Ab immunotherapy exerts powerful,
sometimes deleterious effects on vascular integrity and
function [30,31,58-60]. In addition, direct clinical experi-
ence has confirmed that individuals harboring ApoEε4
genes are more likely to suffer severe adverse effects
from amyloid immunotherapy. While it is unclear
whether these responses are a cause or consequence of
vascular pathology, they unfortunately do reveal that
AN-1792 is contraindicated outright or must be applied
with caution in the patient subpopulation known to be
most at risk for AD development.
The enhanced production of TNF-a in the immunized
AD cases revealed an ongoing inflammatory reaction in
part generated by antigen-antibody interactions. Opsoni-
zation of Ab and subsequent uptake by microglia
through the Fc receptors stimulates the secretion of
molecules such as interleukin (IL)-1, IL-6, IL-10, TNF-a
and macrophage colony stimulating factor that promote
neuroinflammation and opening of the BBB. These para-
doxical reactions need to be considered in the design of
effective immunotherapies [61]. In addition, TNF-a sup-
presses Ab degradation by reducing the expression of
insulin degrading enzyme [62].
Despite a decade of promising developments in amy-
loid plaque mitigation, whether the amyloid hypothesis
represents the ultimate mechanistic explanation for
sporadic AD pathology remains undetermined. Regard-
less of the role of amyloid plaques as the leading cause
for dementia, the existing efforts to combat these lesions
need further development. In addition to examining the
pathophysiology underlying the remarkable amyloid pla-
que disruption in the brain following immunotherapy,
an account of the role of peripheral pools in increasing
levels of circulating Ab requires a full mechanistic
explanation.
Conclusions
In summary, our results revealed a wide variation in the
overall proportions of Ab40 and Ab42 peptides among the
immunized individuals, with a general predominance of
SDS-stable dimeric forms over monomeric ones. In addi-
tion, SELDI-TOF MS demonstrated an array of Ab-related
peptides, mainly extending towards the C-terminal
domain of APP that, in part, may result from the strong
extraction conditions that we utilized, capable of totally
dispersing membrane structures. Pro-inflammatory
TNF-a levels were significantly increased in the GM of
immunized AD cases compared to the NDC and non-
immunized AD groups. Amyloid-b immunization resulted
in amyloid plaque disruption and clearance to widely
divergent extents, with levels ranging from below the limit
of detection to values exceeding those seen in non-immu-
nized AD cases in ELISA. These idiosyncratic responses,
in conjunction with the wide range of biological and
pathological variation that characterize aging and disease
conditions, will make it difficult to interpret data derived
from therapeutic investigations. Moreover, this variation
enormously complicates recognition of suitable biomar-
kers for AD. Our data suggest that the therapeutic out-
come will depend on the quality and the quantity of
administered immunogens and the patient’s immunologi-
cal responses with the ApoE phenotype appearing to mod-
ulate the effectiveness of plaque and vascular amyloid
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removal. In attempting to deploy Ab antibodies as AD
therapeutic tools, the full range of physicochemical prop-
erties of the Ab peptides in humans should be considered.
Although in some cases the removal of amyloid plaques
by AN-1792 appeared to be impressive, there were no
proportionate alterations in the clinical progression of
Alzheimer’s disease.
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